7 results about "HPV Antigen" patented technology

The present application provides a T cell receptor (TCR) having the property of binding to YMLDLQPET-HLA A0201 complex; and the binding affinity of the TCR to the YMLDLQPET-HLA A0201 complex is at least 2 times the binding affinity of the wild-type TCR to the YMLDLQPET-HLA A0201 complex. The present application also provides a fusion molecule of such TCR and a therapeutic agent. Such TCR can be used alone or in combination with a therapeutic agent to target tumor cells presenting YMLDLQPET-HLA A0201 complex.

Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and / or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and / or for modulating an immune response in an individual with an HPV-associated disease.

Provided are an HPV vaccine containing a nucleic acid molecule encoding an HPV antigen and an immune costimulatory factor, and the use thereof.

The invention discloses a therapeutic vaccine for human papilloma virus infection and a preparation method thereof. In particular to a composition for preventing and / or treating diseases caused by HPV infection. The composition comprises DC cells loaded with HPV antigens and exosomes. The invention also discloses a preparation method of the composition. The therapeutic vaccine provided by the invention comprises a SiHa cell exosome, an MS751 cell exosome and a human DC cell loaded with HPV VLPs (L1 protein virus-like particles of HPV). Experiments show that the therapeutic vaccine can induce and significantly enhance HPV specific CTL immune response, has an obvious killing effect on cervical cancer cells, can enhance anti-tumor immune response, and enhances the immunity of an organism to diseases, thereby achieving a therapeutic effect. The therapeutic vaccine can effectively treat HPV infection and diseases caused by the HPV infection, or prevent deterioration of the HPV infection and the diseases caused by the HPV infection.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and / or for modulating an immune response in an individual with an HPV-associated disease.